Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 17:9:114.
doi: 10.1186/s13023-014-0114-8.

A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease

Tua Vinther-Jensen, Ida U Larsen, Lena E Hjermind, Esben Budtz-Jørgensen, Troels T Nielsen, Anne Nørremølle, Jørgen E Nielsen, Asmus Vogel

A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease

Tua Vinther-Jensen et al. Orphanet J Rare Dis. .

Abstract

Background: Involuntary movements, neuropsychiatric symptoms, and cognitive impairment are all part of the symptom triad in Huntington's disease (HD). Despite the fact that neuropsychiatric symptoms and cognitive decline may be early manifestations of HD, the clinical diagnosis is conventionally based on the presence of involuntary movements and a positive genetic test for the HD CAG repeat expansion. After investigating the frequencies of the triad manifestations in a large outpatient clinical cohort of HD gene-expansion carriers, we propose a new clinical classification.

Methods: In this cross-sectional study, 107 gene-expansion carriers from a Danish outpatient clinic were recruited. All participants underwent neurological examination, psychiatric evaluation and neuropsychological testing. Participants were categorised according to motor symptoms, neuropsychiatric symptoms, the use of psychotropic medication, and cognitive impairment.

Results: Among the motor manifest HD gene-expansion carriers, 51.8% presented with the full symptom triad, 25.0% were defined as cognitively impaired in addition to motor symptoms, and 14.3% had neuropsychiatric symptoms along with motor symptoms. Only 8.9% had isolated motor symptoms. Among gene-expansion carriers without motor symptoms, 39.2% had neuropsychiatric symptoms, were cognitively impaired, or had a combination of the two.

Conclusion: This is the first study to report the frequencies of both motor symptoms, cognitive impairment, and neuropsychiatric symptoms in HD gene-expansion carriers in a national outpatient HD clinical cohort. We found that almost 40% of the gene-expansion carriers without motor symptoms had either neuropsychiatric symptoms, cognitive impairment or both, emphasising that these patients are not premanifest in psychiatric and cognitive terms, suggesting that the current clinical classification is neither necessarily suitable nor helpful for this patient group. Some premanifest gene-expansion carriers may have psychiatric and/or cognitive symptoms caused by reactive stress or other pathology than HD. Acknowledging this fact we, however, suggest classifying all HD gene-expansion carriers into three clinical categories: premanifest, non-motor manifest, and motor manifest.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart used for categorisation of participants into the neuropsychiatric vs. the non-neuropsychiatric groups.
Figure 2
Figure 2
Distribution of cognitive impairment and neuropsychiatric symptoms in the motor manifest HD gene-expansion carriers.
Figure 3
Figure 3
Distribution of cognitive impairment and neuropsychiatric symptoms in the premanifest HD gene-expansion carriers.
See this image and copyright information in PMC

References

    1. Walker FO. Huntington's disease. Semin Neurol. 2007;27:143–150. doi: 10.1055/s-2007-971176. - DOI - PubMed
    1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971–983. doi: 10.1016/0092-8674(93)90585-E. - DOI - PubMed
    1. Huntington G. On Chorea. Med Surg Rep. 1872;26:317–321.
    1. Berrios GE, Wagle AC, Markova IS, Wagle SA, Rosser A, Hodges JR. Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr Scand. 2002;105:224–230. doi: 10.1034/j.1600-0447.2002.0o456.x. - DOI - PubMed
    1. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874–880. doi: 10.1136/jnnp.2007.128728. - DOI - PMC - PubMed

Publication types